tbuckley/cabot-search huggingface dataset:
Commentary on the ASCO Statement on Genetic Testing for Cancer Susceptibility
Authors: Frances M. Visco
Journal: Journal of Clinical Oncology (1996)

Article Tools ARTICLE Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1996.14.5.1737 Journal of Clinical Oncology - published online before print September 21, 2016 Commentary on the ASCO Statement on Genetic Testing for Cancer Susceptibility Frances M. ViscoxFrances M. ViscoSearch for articles by this author Show More National Breast Cancer Coalition, Washington, DC https://doi.org/10.1200/JCO.1996.14.5.1737 PDF "Commentary on the ASCO Statement on Genetic Testing for Cancer Susceptibility." Journal of Clinical Oncology, 14(5), p. 1737© 1996 by American Society of Clinical Oncology
Targeting distinct myeloid cell populations in vivo using polymers, liposomes and microbubbles
Authors: Can Ergen, Felix Heymann, Wa'el Al Rawashdeh, Felix Gremse, Matthias Bartneck, Ulf Panzer, Robert Pola, Michal Pechar, Gert Storm, Nicole Mohr, Matthias Barz, Rudolf Zentel, Fabian Kiessling, Christian Trautwein, Twan Lammers, Frank Tacke
Journal: Biomaterials (2016)
THU0438 Enthesitis in Psoriatic Arthritis and Need for Biological Therapy
Authors: M. Bascuas, J.L. Andreu, I. Millan, M. Cuadros, C. Ramos, M. Espinosa, B.J. Flores, J. Campos, J. Sanz
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Psoriatic arthritis (PsA) is a potentially destructive inflammatory chronic arthropathy, with a wide range of clinical manifestations. Currently, biological therapy (BT) is the second step of treatment after an inadequate response to conventional disease-modifying anti-inflammatory drugs. <h3>Objectives</h3> The goal of our study was to identify baseline characteristics of patients with PsA associated with the need for BT use during the follow-up. <h3>Methods</h3> This is a single-centre, case-control study. Unselected PsA patients diagnosed after December 31st, 1999 and fulfilling CASPAR classification criteria were included. Reviewing medical records identified epidemiological, clinical, analytical and imaging features. The main outcome was the need of BT during the follow-up. The local ethical committee authorized the study. Chi-square, Student t test, and Mann-Whitney U test were used to establish statistical significance in the univariate analysis. Logistic regression was used for the multivariate analysis. A p&lt;0.05 was considered significant. <h3>Results</h3> One hundred and fifty-nine patients were included (75 women and 84 men), with a mean age of 48 years. During the follow-up, 66 patients (41%) needed BT (BT+ patients). No significant differences in age, sex, race, presence of cardiovascular risk factors, smoking, alcohol consumption, initial joint pattern, presence of dactylitis, presence of onychopathy, HLA B27 positivity, presence of radiographic erosions, presence of axial radiographic involvement, mean C-reactive protein, or mean erythrocyte sedimentation rate were found in BT+ patients when compared with BT negative (BT−) patients. Twenty per cent of BT− patients had enthesitis at the beginning, compared with 39% of BT+ patients [Odds ratio 2.53 (CI 95%: 1.25–5.12); p=0.009]. Mean time from the onset of symptoms to the first appointment with a rheumatologist was significantly associated with the need for further use of BT (20 weeks in BT− patients versus 108 weeks in BT+ patients; p&lt;0.001). Multivariate analysis showed that the delay in rheumatology consultation and presence of enthesitis were independent factors significantly associated with the need for BT. <h3>Conclusions</h3> In PsA patients, the initial presence of enthesitis is an independent risk factor associated with the need for biological therapy during the follow-up. <h3>Disclosure of Interest</h3> None declared
Outcome in Philadelphia Chromosome Positive (Ph+) Adult ALL Patients (Pts) May Be More Determined by CD25 Expression Than by Ph Status Per Se.
Authors: Elisabeth Paietta, Xiaochun Li, Sue Richards, Janis Racevskis, Gordon W. Dewald, Jacob M. Rowe, Martin S Tallman, Hillard M Lazarus, Mark R. Litzow, Anthony H. Goldstone, Peter Wiernik
Journal: Blood (2008)
SAT0461 Efficacy of Hyaluronic Acid in Small Joints Osteoarthritis (OA) – The Results of Multicenter Randomized Placebo-Controlled 48 Weeks Study
Authors: E. Tsvetkova, L. Denisov, E. Nasonov, E. Panasyuk, E. Sharapova, N. Kashevarova, S. Anikin, L. Menshikova, E. Smidt, D. Goryachev
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Objectives</h3> Assessment of the efficacy, tolerability and aftereffect period on the single administration into Ist carpometacarpal and Ist metatarsophalangeal OA joints of 1.0ml (20mg) of hyaluronic acid (Durolane SJ) as compared with placebo. <h3>Methods</h3> The study included 120 pts with OA of small hand joints or feet, pain intensity &gt;40mm by VAS and consisted of two phases: "blind" phase up to 24 weeks, period of open assessment of long term efficacy results – 48 weeks. The efficacy was assessed by 40% pain subsiding, index AUSCAN (for the hand), daily dose of NSAID, total effect assessment by VAS. <h3>Results</h3> Both groups were comparable by basic clinical criteria. 40% pain subsiding by VAS (mm) was noted in experimental group to 24th week in 79.7%, in the placebo group – 30% (chi-square: p&lt;10<sup>–5)</sup> relation of chances (OR) equal to 9.1 (3.9–21.1). Dispersion analyses of pain, stiffness and function by AUSCAN index revealed reliable differences between Durolane SJ and placebo. Adverse effects related to the therapy were not found. Effect, achieved to 24th week of observation included pain, stiffness, functional status, general assessment of condition by the therapist and patient, was preserved without changes to 48th week. <h3>Conclusions</h3> High efficacy and 48 weeks considerable duration of aftereffect of single administration of Durolane SJ (small joints) as compared to placebo was demonstrated. <h3>Disclosure of Interest</h3> None declared
THU0344 Osteoporosis and Vertebral Fractures in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis
Authors: M. García-Carrasco, A. Rojas-Villarraga, N. Molano-González, P. Soto-Santillán, C. Mendoza-Pinto
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Observational studies have indicated a high but heterogeneous prevalence of low bone mineral density (BMD) and vertebral fractures (VR) in patients with systemic lupus erythematosus (SLE). <h3>Objectives</h3> To evaluate the relationship between SLE and BMD, osteoporosis and the risk of vertebral fracture. <h3>Methods</h3> A systematic review and meta-regression analyses were carried out according to the Preferred Reporting Items for Systematic Meta-Analyses (PRISMA) guidelines. Articles were identified from electronic databases (PubMed, Embase, VHL, SciELO and the Cochrane Library). The search was conducted using MesH terms, Boolean operators and keywords, which included "systemic lupus erythematosus", "osteoporosis", "bone mineral density", and "vertebral fractures". Prospective longitudinal and cross-sectional studies were considered for review without language restrictions. Articles were screened for suitability. Those selected were evaluated by two investigators, who extracted information on study characteristics, outcomes of interest, and risk of bias, and summarized the strength of evidence. Data was extracted when studies met inclusion criteria and were of sufficient quality. BMD, reported as the mean ± standard deviation evaluated by dual-energy X-ray absorptiometry (DXA), was analyzed including information on SLE cases and controls, treatment, menopausal status and fractures by meta-regression analysis adjusted by anatomical region. Data were analyzed using the Metafor package in R (3.0.2 version). <h3>Results</h3> In total 49 articles were identified and analyzed (12, 593 SLE cases/six anatomical regions and 14,235 controls/six anatomical regions). SLE women, but not SLE men, had a lower BMD than healthy controls (p&lt;0.0001). When only SLE patients were analyzed, the BMD did not significantly differ between patients who had or had not received corticosteroid (CTS) therapy. Unsurprisingly, postmenopausal SLE patients had a lower BMD (lumbar spine and total hip) compared with premenopausal patients (p&lt;0.0001). The BMD did not differ in patients with and without fractures. <h3>Conclusions</h3> This systematic review and meta-regression analysis shows that women with SLE had a higher risk of low BMD than healthy controls. The data did not show that CTS therapy had an impact on BMD. <h3>References</h3> Bultink IE. Osteoporosis and fractures in systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2012;64:2–8. <h3>Acknowledgement</h3> We would like to thank David Buss for his valuable guidance and advice during this project. <h3>Disclosure of Interest</h3> None declared
Short Time Latency in Infant Leukemia with ETV6/RUNX1 fusion Gene
Authors: Mariana Emerenciano, Silvia Bungaro, Giovanni Cazzaniga, Maria Dolores Fonseca Dorea, Virginia Maria Coser, Isis Quezado Magalhaes, Andrea Biondi, Maria S. Pombo-de-Oliveira
Journal: Blood (2008)
An Activating KRAS Mutation in Imatinib Resistant Chronic Myeloid Leukemia.
Authors: Anupriya Agarwal, Christopher A. Eide, Amy Harlow, Jeffrey W. Tyner, Michael J. Mauro, Christopher L. Corless, Michael C. Heinrich, Brian J. Druker, Michael W. Deininger
Journal: Blood (2007)
Single-Nucleotide Variations Defining Previously Unreported ADAMTS13 Haplotypes Are Associated With Differential Expression and Activity Of The VWF-Cleaving Protease In a Salvadoran Congenital Thrombotic Thrombocytopenic Purpura Family
Authors: Benjamin Kim, Zachary A. Hing, Andrew Wu, Tal Schiller, Evi B. Struble, David Liuwantara, Pamela H. Kempert, Eric J. Broxham, Nathan C. Edwards, Victor J. Marder, Vijaya L. Simhadri, Zuben E. Sauna, Tom E. Howard, Chava Kimchi-Sarfaty
Journal: Blood (2013)
AB0425 Tac-Tic Use of Tacrolimus-Based Regimens in Lupus Nephritis
Authors: T. Kraaij, O.W. Bredewold, T. Huizinga, T. Rabelink, O. Teng
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Current guidelines do not mention tacrolimus as a treatment option and no consensus has been reported on the role of tacrolimus in active LN. Recent clinical trials have reported positive effects of tacrolimus-based (TAC) regimens for treatment of lupus nephritis (LN). <h3>Objectives</h3> With this systematic review and meta-analysis, we aimed to translate recent outcomes on tacrolimus-based regimens for LN treatment into clinical practice. <h3>Methods</h3> We identified from various databases every clinical studies investigating TAC regimens in LN. Studies were summarized on the basis of treatment target (induction or maintenance), concomitant immunosuppression and quality of the data. A meta-analysis was performed for the efficacy of TAC regimen as induction treatment, maintenance treatment as well as safety. <h3>Results</h3> 239 studies were identified from which 24 were clinical studies performed in LN patients: 6 case series, 9 cohort studies, 3 case-control studies (CCS) and 6 randomized controlled trials (RCTs). Further analysis of the 9 controlled trials showed that 7 studies investigated tacrolimus in combination with steroids and 2 tacrolimus with mycophenolate plus steroids. 4 RCTs investigated TAC regimens as induction treatment and 2 RCTs as maintenance treatment. Strikingly, there was no consensus in any of the studies regarding tacrolimus dosing and target trough levels. Importantly, all the studies were performed in LN patients of Asian ethnicity. A meta-analysis of TAC regimens for induction treatment showed a significantly higher complete response (RR 1.18, 95% CI 1.04–1.34, p=0.01) and a significantly lower no response rate (RR 0.71, 95% CI 0.56–0.90, p&lt;0.01). With respect to safety, no clear differences between TAC regimens and conventional treatment were observed. <h3>Conclusions</h3> Current studies on TAC regimens for LN are limited, heterogenous and predominant uncontrolled studies in patients of Asian ethnicity. A significant, clinical efficacy of TAC regimens as induction treatment was found however cannot be extrapolated beyond Asian LN patient groups. Clearly, these results mandate further confirmation in multi-ethnic, randomized trials. <h3>Disclosure of Interest</h3> None declared
AB0538 Assessment of Neurological Manifestations in Temporal Arteritis:
Authors: C. Aranda-Valera, S. García, I. Monjo, M.J. Rodríguez, E. Martín-Mola, E. De Miguel
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Temporal Arteritis (TA) is a vasculitis characterized by systemic and ischemic symptoms that concern fundamentally supraaortic blood vessels. The neurological clinic can be expressed as: headache, visual alterations, affection of cranial nerves, transient ischemic attack (TIA) or ischemic stroke in carotid or vertebrobasilar territory. The ocular affection is the most frequent but other neurological ischemic affections, not retinals, are not rare but they often occur unnoticed and are attributed to atherosclerosis given the age of the patients. Being a treatable and preventable process, there is an opportunity to improve the diagnosis of this affection. <h3>Objectives</h3> Assess the vascular events of supraaortic blood vessels, ocular vessels and non ocular vessels in our vasculitis surgery. <h3>Methods</h3> A retrospective study was carried out on the clinical history of the patients sent to our vasculitis surgery on suspicion of TA. The diagnosis of arteritis or nonarteritic neurological affection was realized in agreement with usual clinical criteria. The variables registered were age and sex, cardiovascular risk factors (CVR), clinical manifestations,VSG and PCR values, the final diagnosis and the results of the biopsy and the ultrasound examination, as well as the number of affected branches, brain TAC and MRI. The statistical analysis was realized by means of the software program SPSS Statistics version 20.0. <h3>Results</h3> Of the 163 patients studied, 112 were women and 51 men (31,3% vs 68,7%). One hundred thirteen patients (59,32%) had definite diagnosis of TA while 50 (30,68%) presented other diagnoses. Of the total of the patients, 59 (24 men and 35 women) presented neurological clinic: diplopía 10, loss of vision 48, TIA 7 and ACVA 4. Of these 42 were diagnosed with arteritic neurological affections (secondary to TA): 6 diplopía, 35 loss of vision, 4 TIA and 2 ACVA. Among the patients with nonarteritic and arteritic neurological events no differences were found for sex, VSG, PCR, blurry vision, fever, loss of vision, diplopía, TIA, ACVA, CVR, smoking and atrial fibrillation (AF): there was only significant differences for age. The analysis of the patients diagnosed with TA, withand without neurological events, appear in the table. <h3>Conclusions</h3> Non ocular central neuroischemic events are frequent and affect 10,62% of the patients with TA. Among the patients with TA the neuroischemic risk associates to being a male, advanced age, a greater number of affected branches in ultrasound examination and to the presence of headache. <h3>Disclosure of Interest</h3> None declared
Clinical and Histopathologic Ocular Findings in Disseminated Mycobacterium chimaera Infection after Cardiothoracic Surgery
Authors: Sandrine A. Zweifel, Daniela Mihic-Probst, Christine A. Curcio, Daniel Barthelmes, Andrea Thielken, Peter M. Keller, Barbara Hasse, Christian Böni
Journal: Ophthalmology (2016)
Enhanced MRI Evaluation of Children with Sickle Cell Following Hematopoietic Stem Cell Transplantation
Authors: Nancy S. Green, Monica Bhatia, Erica Griffin, Mahvish Qureshi, Courtney Briamonte, Mirko Savone, Stephen Sands, Margaret T. Lee, Angela Lignelli, Adam M. Brickman
Journal: Blood (2015)
Prognostic Impact of Transfusions Intensity on Survival and Development of Thrombocytopenia in Newly Diagnosed Lower-Risk MDS Patients Participating in the European Leukemianet EU-MDS Registry
Authors: Louise De Swart, Tom Johnston, Alexandra Smith, Pierre Fenaux, Argiris Symeonidis, Jaroslav Cermak, Eva Hellström-Lindberg, Guillermo Sanz, Reinhard Stauder, Luca Malcovati, Ulrich Germing, Gerwin Huls, Mette Skov Holm, Moshe Mittelman, Krzysztof Madry, Aurelia Tatic, Antonio Medina Almeida, Aleksandar Savic, Sophie Park, Odile Beyne-Rauzy, Raphaël Itzykson, Corine van Marrewijk, David Bowen, Theo de Witte
Journal: Blood (2015)
AB0526 Serum Ferritin as A Marker of Activity in Patients with Anca-Associated Vasculitis
Authors: H. Küçük, Ö. Varan, B. Bitik, M.A. Öztürk, B. Göker, S. Haznedaroğlu, A. Tufan
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> ANCA-associated vasculitides (AAVs) are a group of systemic inflammatory disorders with substantial morbidity and mortality. Alveolar hemorrhage and gastrointestinal involvement are major causes of death in these disorders. Markers that measure activity and predict prognosis are needed. Serum ferritin levels are shown to be associated with activity and prognosis of certain rheumatic diseases such as antiphospholipid syndrome, dermatomyositis and systemic lupus erythematosus. <h3>Objectives</h3> To investigate association between serum ferritin with acute phase reactants and major disease manifestations in AAV.To investigate association between serum ferritin with acute phase reactants and major disease manifestations in AAV. <h3>Methods</h3> Retrospective charts of 40 patients (22 males, mean age 49±15 years) with AAV were utilized. Patients fulfilling Chapel hill classification criteria for AAV and those with at least 6 months of follow up were included. Disease activity of AAV was assessed with Birmingham vasculitis activity score (BVAS). Serum ferritin, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) and creatinine values were obtained from hospital records. Creatinine clearance (CrCl) was calculated with MDRD formula. Association between serum ferritin with acute phase reactants and major disease manifestations were analyzed with Spearman rank and Mann Whitney U tests. <h3>Results</h3> Among 40 patients with AAV, 14 had pulmonary hemorrhage, eight had end stage renal disease, three mesenteric ischemia and four died in the follow up (two due to alveolar, one cerebral and one GI hemorrhage). Serum ferritin was not correlated with ESR and CRP. However, there was a significant correlation between BVAS and initial CrCl (r=0.61, p&lt;0.001 and r= -0.59, p&lt;0.001, respectively). Serum ferritin values were higher in patients with pulmonary hemorrhage (median (IQR), 65.8 (207) vs 1041 (1281) ng/mL, p&lt;0.001) and in those four patients who died in the initial six-moths follow up period (206.8 (556) vs 1362 (1292) ng/mL, p&lt;0.014). <h3>Conclusions</h3> Serum ferritin could be used as a marker of activity because of its ability to reflect disease severity which has already been shown in other systemic inflammatory disorders. Association between serum ferritin with other manifestations of AAVs remain to be elucidated in the large population studies. <h3>References</h3> Chen, Y.X., et al., Analyzing fatal cases of Chinese patients with primary antineutrophil cytoplasmic antibodies-associated renal vasculitis: a 10-year retrospective study. Kidney Blood Press Res, 2008. 31(5): p. 343–9. Hogan, P.C., et al., Biomarkers Predict Relapse in Granulomatosis with Polyangiitis. J Biomark, 2014. <h3>Disclosure of Interest</h3> None declared
Avicenna—A Pioneer in Dermatology
Authors: Fatemeh Atarzadeh, Mojtaba Heydari, Mohammad Reza Sanaye, Gholamreza Amin
Journal: JAMA Dermatology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Velcade, Thalidomide and Dexamethasone (VTD) Regimen Followed by High-Dose Chemotherapy Plus Autologous Stem Cell Transplant (HDT-ASCT) as Front-Line treatment in Newly Diagnosed Multiple Myeloma (MM) Patients: Preliminary Results of An ongoing Open Label Study
Authors: Nicola Di Renzo, Elsa Pennese, Pasquale Forese, Giovanni Reddiconto, Rosella Matera, Carolina Vergine, Antonia Falcone, Nicola Cascavilla
Journal: Blood (2008)
Alemtuzumab in the Treatment of Steroid Refractory Acute Graft-Versus-Host Disease.
Authors: David Gomez-Almaguer, Guillermo Ruiz-Arguelles, Oscar Gonzalez-Llano, Olga G. Cantu, Cesar H. Gutierrez, Jose Carlos Jaime-Perez, Luz Tarin-Arzaga, Sergio Giralt
Journal: Blood (2006)